Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00959582 | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) | PHASE1 | COMPLETED | 42 | — | — | Sep 1, 2009 | Oct 1, 2011 | Jan 22, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 18-F-FDG PET/CT imaging |
| Name | Type | Description |
|---|---|---|
| Comparator: 18-F-FDG PET/CT and Volumetric CT | PROCEDURE | Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing. |
Inclusion Criteria: * Patient has ovarian, primary peritoneal, or fallopian tube cancer * Patient has first or subsequent relapse * Patient has had at least on prior platinum-based treatment for ovarian cancer * Patient is scheduled to receive treatment with carboplatin or cisplatin monotherapy or ...